ライフサイエンスコーパス: zileuton

1 logy, which were absent in mice treated with zileuton.

2 guinea pig in vivo models and was similar to zileuton.

3 anti-PlGF Ab or the 5-lipoxygenase inhibitor zileuton.

4 Administration of zileuton 1 day before infection and through day 5 after

5 ebo), and no patients treated with 600 mg of zileuton, 400 mg of zileuton, or placebo, respectively.

6 Patients were randomly assigned to: (a) zileuton 600 mg PO qid, (b) celecoxib 400 mg PO bid, or

7 late (270 and 540 mg/kg), MK-886 (30 mg/kg), Zileuton (600 and 1200 mg/kg), or combinations containin

8 edema model, 40 was more potent than either zileuton (a 5-LO inhibitor) or BN 50739 (a PAF receptor

9 ercise-induced asthma received either 600 mg zileuton, a 5-lipoxygenase inhibitor, or a placebo four

10 nistration of Manoalide, a PLA2 inhibitor or Zileuton, a 5-LOX inhibitor with VPC reversed the protec

11 looxygenase-2 (COX-2) inhibitor; PIO+ATV and zileuton, a selective 5-lipoxygenase inhibitor; or zileu

12 a deposition in the brains of mice receiving zileuton, a selective and specific 5-LO inhibitor, was s

13 Coincubation of FMLP with zileuton, a selective inhibitor of 5-lipoxygenase, cause

14 which results in high Hcy, or the Diet plus zileuton, a specific ALOX5 inhibitor, for 7 months.

15 Both valdecoxib and zileuton abrogated the PIO+ATV increase in 15-epi-LXA4,

16 OX-2], celecoxib and 5-lipoxygenase [5-LOX], zileuton) added to chemotherapy would improve outcome in

17 the PIO+ATV increase in 15-epi-LXA4, whereas zileuton alone had no effect.

18 on, a selective 5-lipoxygenase inhibitor; or zileuton alone.

19 D-fed wild-type mice with the 5-LO inhibitor Zileuton also results in a reduction of AT macrophages a

20 These data also suggest that zileuton and anti-PlGF Ab could be promising therapies t

21 e effect of pharmacologic 5-LO inhibition by zileuton and LTB4 inhibition by CP-105,696.

22 ion of endogenous leukotriene synthesis with zileuton and MK-886 dramatically attenuated phagocytosis

23 ranlukast, and the 5-lipoxygenase inhibitor, zileuton, are unique in their ability to target specific

24 elecoxib 400 mg PO bid, or (c) celecoxib and zileuton at the same doses.

25 The results indicate that neither zileuton, Bay x 1005, nor Bay y 1015 inhibited exudate p

26 nhibitors (AA861, nordihydroguaiaretic acid, zileuton) but not a flavoenzyme inhibitor (diphenyleneio

27 ein antagonist MK 886 and the 5-LO inhibitor zileuton, but not by cyclooxygenase inhibitors.

28 At 10(-10) M zileuton, cell migration caused by FMLP was decreased by

29 ting 12-LOX (CDC, Baicalein), but not 5-LOX (Zileuton) dose-dependently attenuated tactile allodynia.

30 t (6.1%) of 132 patients receiving 600 mg of zileuton four times a day required corticosteroid treatm

31 ssments significantly improved in the 600-mg zileuton group and not in the placebo group (P=.007 for

32 he average FEV1 improved 15.7% in the 600-mg zileuton group vs 7.7% in the placebo group (P=.006).

33 inutes after the completion of exercise, the zileuton group's FEV1 was 85.76% of the preexercise valu

34 gonist, zafirlukast, and the 5-LO inhibitor, zileuton, improve pulmonary function and decrease daytim

35 ay x 1005 and Bay y 1015, were compared with zileuton in terms of their ability to decrease exudate v

36 The administration of zileuton inhibited bronchospasm after exercise challenge

37 ned the effects of the leukotriene inhibitor zileuton on clinical features and lung function.

38 the effects of the 5-lipoxygenase inhibitor zileuton on these responses.

39 Thirteen weeks later, Accolate, Zileuton (only the high concentration), and combinations

40 Treatment with 600 mg or 400 mg of zileuton or placebo (each taken four times daily.)

41 also inhibited by pertussis toxin but not by zileuton or WEB 2086.

42 s treated with 600 mg of zileuton, 400 mg of zileuton, or placebo, respectively.

43 200 +/- 3,620 eos/cm resulted after 10(-6) M zileuton (p < 0.001 versus FMLP).

44 d maximally to 1.15 +/- 2.51% after 10(-8) M zileuton (p < 0.02).

45 Furthermore, in vitro studies confirmed that zileuton prevents Abeta formation by modulating gamma-se

46 At week 43, MK-886, Accolate, and Zileuton reduced lung tumor multiplicity by 37.8, 29.5,

47 Treatment with the 5-lipoxygenase inhibitor zileuton reduced postantigen BALF eosinophil count by 68

48 parable efficacy as reported for aspirin and zileuton, respectively.

49 ve abilities to reconstitute phagocytosis in zileuton-treated rat alveolar macrophages and in alveola

50 Zileuton treatment did not induce any change in the stea

51 receiving 5-LO-deficient cell transplant or zileuton treatment had prolonged survival, reduced GVHD

52 Five minutes after exercise, the FVC after zileuton was 92.76% of the preexercise value, as compare

53 aximum percent change in baseline FEV1 after zileuton was a 15.58% decrement from the preexercise lev

54 ne pathway inhibitors, Accolate, MK-886, and Zileuton, were evaluated as chemopreventive agents in fe

55 ienes were in the range of the approved drug zileuton, which further underlines the biological import

56 the high concentration), and combinations of Zileuton with either Accolate or MK-886 reduced lung tum

57 This study examined whether zileuton (ZL), a structural analog of hydroxyurea, posse